SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

17 May 2023 Evaluate
The company witnessed a 11.50% growth in the revenue at Rs. 3145.84 millions for the quarter ended March 2023 as compared to Rs. 2821.42 millions during the year-ago period.Net profit for the quarter ended March 2023 increases to Rs. 878.41  millions from Rs. 867.09 millions.OP of the company witnessed a marginal growth to 1157.50 millions from 1106.76 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 3145.84 2821.42 11.50 13307.25 12157.30 9.46 13307.25 12157.30 9.46
Other Income 42.60 90.52 -52.94 172.64 289.89 -40.45 172.64 289.89 -40.45
PBIDT 1157.50 1106.76 4.58 5223.78 5129.84 1.83 5223.78 5129.84 1.83
Interest 29.56 9.77 202.56 208.10 29.91 595.75 208.10 29.91 595.75
PBDT 1127.94 1096.99 2.82 5015.68 5099.93 -1.65 5015.68 5099.93 -1.65
Depreciation 172.84 150.70 14.69 646.57 514.55 25.66 646.57 514.55 25.66
PBT 955.10 946.29 0.93 4369.11 4585.38 -4.72 4369.11 4585.38 -4.72
TAX 76.69 79.20 -3.17 389.03 413.46 -5.91 389.03 413.46 -5.91
Deferred Tax -93.36 6.24 -1596.15 -375.93 -388.26 -3.18 -375.93 -388.26 -3.18
PAT 878.41 867.09 1.31 3980.08 4171.92 -4.60 3980.08 4171.92 -4.60
Equity 135.99 135.93 0.04 135.99 135.93 0.04 135.99 135.93 0.04
PBIDTM(%) 36.79 39.23 -6.20 39.26 42.20 -6.97 39.26 42.20 -6.97

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×